What Will Happen to Ceapro Inc. Next? The Stock Just Has Upped A Lot

 What Will Happen to Ceapro Inc. Next? The Stock Just Has Upped A Lot

The stock of Ceapro Inc. (CVE:CZO) is a huge mover today! The stock last traded at $1.45 per share. It is down 6.00% since October 19, 2016 and is uptrending. It has outperformed by 1.57% the S&P500.
The move comes after 9 months positive chart setup for the $106.14 million company. It was reported on Nov, 18 by Barchart.com. We have $2.09 PT which if reached, will make CVE:CZO worth $46.70 million more.

More important recent Ceapro Inc. (CVE:CZO) news were published by: Seekingalpha.com which released: “Ceapro: A Small, Profitable, Fast-Growing Biotechnology Company” on November 04, 2016, also Marketwired.com published article titled: “Ceapro Inc. Announces the Grand Opening of New Bio-processing Extraction Facility”, Marketwired.com published: “Ceapro Inc. Reports Second Quarter 2016 Financial and Operational Results” on August 24, 2016. More interesting news about Ceapro Inc. (CVE:CZO) was released by: Marketwired.com and their article: “Ceapro Inc. Presents Its PGX Technology at the 15th European Meeting on …” with publication date: May 09, 2016.

Ceapro Inc. is a Canada-based growth-stage biotechnology company. The company has a market cap of $106.14 million. The Company’s primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human and animal health industries using technology, natural and renewable resources. It has a 12.2 P/E ratio. The Company’s products include a commercial line of natural active ingredients, including beta glucan, avenanthramides , oat powder, oat oil, oat peptides and lupin peptides, which are marketed to the personal care, cosmetic, medical and animal health industries, and Veterinary therapeutic products, including an oat shampoo, an ear cleanser and a dermal complex/conditioner, which are manufactured and marketed to veterinarians in Japan and Asia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment